Results 211 to 220 of about 400,479 (343)

Systematic review: Safety and efficacy of atomoxetine in children and adolescents with autism spectrum disorder

JCPP Advances, EarlyView.
This systematic review aimed to assess the current evidence on the efficacy and safety of Atomoxetine in common clinical symptoms of autism spectrum disorder (ASD) for children and adolescents. With limited studies available, there is a need for more high‐power studies for the use of Atomoxetine in children and adolescents with autism spectrum disorder.
Nihit Gupta, Daniel Boyes, Hunter Hanlon‐Taylor, Mayank Gupta   +3 more
wiley   +1 more source

Association between the Planetary Health Diet Index and chronic constipation and diarrhea risk in general population: A cross-sectional analysis of NHANES. [PDF]

Medicine (Baltimore)
Qi R, Zhai H, Xu D, Wen Y, Xu S.
europepmc   +1 more source

Advantages of anti‐endomisium evaluation in children with low titers of anti‐transglutaminase antibodies: A retrospective study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Diagnosing celiac disease (CD) via esophagogastroduodenoscopy (EGDS) is necessary when anti‐transglutaminase (anti‐TG) antibody levels are below 10× the upper limit of normal (ULN). This study evaluates patients with low anti‐TG titers, particularly when endomysial antibodies (EMA) are negative.
Roberta Mandile, Chiara Esposito, Maria Pia Basile, Mariantonia Maglio, Riccardo Troncone, Renata Auricchio   +5 more
wiley   +1 more source

Study of Types of Pathophysiologic Patterns of Chronic Constipation and Its Correlation With Clinical Features. [PDF]

JGH Open
Jain AK, Yadav S, Jain S, Sircar S.
europepmc   +1 more source

Healthcare resource utilization and cost in pediatric celiac disease: A case‐control study using German insurance data

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Celiac disease (CeD) is a life‐long systemic immune‐mediated disorder. Data on burden and cost of CeD in children are scarce. We assessed healthcare resource utilization (HCRU) and cost of healthcare services of newly diagnosed children in Germany.
Sibylle Koletzko, Svitlana Schnaidt, Leonarda Serdani‐Neuhaus, Juliane Sünwoldt, Christina Dünweber, Bernd Bokemeyer   +5 more
wiley   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

Depressive Symptoms, Dietary Patterns and Other Factors Associated with Constipation in Middle-Aged Adults from Kielce District in Poland: A Cross-Sectional Study. [PDF]

J Clin Med
Głuszek-Osuch M, Cieśla E, Sobaś K, Suliga E, Głuszek S.   +4 more
europepmc   +1 more source

Lactobacillus rhamnosus LRa05 Alleviates Constipation via Triaxial Modulation of Gut Motility, Microbiota Dynamics, and SCFA Metabolism

Jingxin Zhang, Qian Li, Shanshan Liu, Ning Wang, Yu Song, Tao Wu, Min Zhang   +6 more
openalex   +2 more sources

The validated French CFAbd‐Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Multiorgan abdominal involvement is a hallmark of Cystic fibrosis (CF). The CFAbd‐Score© is the first CF‐specific gastrointestinal patient reported outcome‐measure (PROM) developed following FDA‐guidelines. The PROM has proved to sensitively differentiate people with CF (pwCF) from healthy controls (HC).
Isabelle Sermet‐Gaudelus, Pauline Sadrieh, Anne Sophie Bonnel, Raphael Enaud, Nathalie Wizla, Jeanne Languepin, Ambre Nangui, Audrey Deelawon, Johanna Rave, Samira Dabelow, Anton Barucha, Carlos Zagoya, Franziska Duckstein, Jochen Georg Mainz   +13 more
wiley   +1 more source

Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom, Aaron C. Tan, Erminia Massarelli, Vivek Subbiah, Valentina Boni, Bruce Robinson, Lori J. Wirth, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Caroline E. McCoach   +11 more
wiley   +1 more source